Veraxa Biotech Holding Stock
Veraxa Biotech Holding AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- CEO
- Christoph Antz
- Employees
- 8
- Market cap
- $157 M
- IPO
- 09/06/2026
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company that was formed through a merger with Voyager Acquisition Corp. Headquartered in Heidelberg, Germany, the company is listed on the NASDAQ. The business model focuses on the development of next-generation cancer therapies. Specifically, the company…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Veraxa Biotech Holding stock: price history
1D
+0.9%
1W
-11.9%
1M
-26.5%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Veraxa Biotech Holding stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 06/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Veraxa Biotech Holding AG is a biopharmaceutical company in the clinical development phase, established through a merger with Voyager Acquisition Corp. The primary focus is on the development of innovative cancer therapies, with particular emphasis on antibody-drug conjugates and bispecific T-cell engagers. As the company is currently in an early research and development stage, no revenues are being generated from the sale of products at present.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Veraxa Biotech Holding
Free float & liquidity
FREE FLOAT
8.9%
FLOAT SHARES
12,608,862
AVG. DAILY VOLUME (30D)
340,240
Insider transactions (SEC)
Antz Christoph Rudiger
Baumann Oliver Rolf
Comparable stocks
Frequently asked questions about Veraxa Biotech Holding stock
What does Veraxa Biotech Holding do?
Veraxa Biotech Holding AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Germany.
The CEO is Christoph Antz, the company employs around 8 people.
The IPO was on 09/06/2026; the stock trades on NASDAQ under the ticker VRXA.
Does Veraxa Biotech Holding pay a dividend?
No, Veraxa Biotech Holding currently does not pay a dividend.
Which stocks are comparable to Veraxa Biotech Holding?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Veraxa Biotech Holding stock analyzed?
Clicking "Analyze stock" lets five strategies assess Veraxa Biotech Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.